21
views
0
recommends
+1 Recommend
2 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Chronic pain following COVID-19: implications for rehabilitation

      editorial

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Managing the immediate demands of the current COVID-19 global pandemic has tested many healthcare systems across the world, to their limits. As we move forward, new challenges due the impact of this must be faced. In the months since the initial outbreak of COVID-19 in December 2019, worldwide there have been more than 4.2 millions cases of infection with the SARS-Cov-2 virus reported 1 . However, the rapidity of spread appears to be slowing, the curve is flattening in many countries, and attention is now turning towards how the international healthcare community will address the ongoing needs of those most significantly affected by the pandemic. Recent UK data (covering February-April 2020) suggests 17% of cases admitted to hospital require support in high dependency or critical care environments, and of those just over 50% require mechanical ventilation 2 . About 20% of those requiring mechanical ventilation will be discharged with a further 27% receiving ongoing care. Critical care survival in other countries including Italy, the US and China has been reported as 16-37%, although many cohorts include those receiving ongoing care in ICU3, 4, 5. Given the number of global infections, this suggests a cohort of critically ill survivors of unprecedented size. The treatment needs of COVID-19 survivors are not yet fully appreciated. Although initially assumed to be a respiratory disease, it is now clear that it affects a variety of systems. Multi-organ failure can occur, with reports of cardiac, renal, haematological and neurological effects in the acute stages. It is likely therefore, that these survivors will have significant multi-domain impairment requiring ongoing support. There has been a recent ‘call to action’ amongst the rehabilitation community to act quickly to ensure adequate resources to provide early phase, multidisciplinary interventions to promote physical and psychological recovery 6 . We can perhaps learn from previous studies of critical care survivorship, which has been relatively neglected until recently. This complex challenge has been termed post-intensive care syndrome (PICS) 7 . It incorporates the cognitive, physical and psychological dysfunction reported following ICU discharge that can have profound effects on quality of life. Chronic pain is often part of this, but how this additional co-morbidity affects critical care survivors is poorly understood. Estimates of chronic pain prevalence following ICU vary from 14-77% depending on timescale, method of measurement and population 8 . Pain also appears to be an important factor affecting ability to return to work and quality of life up to 5 years following discharge 9 . It is likely that those surviving critical illness with COVID-19 will be at particular risk of developing chronic pain. There are a number of reasons why this may be the case (Figure 1 ). Figure 1 Potential risk factors for development of chronic pain following COVID-19. (PTSD=post-traumatic stress disorder). Figure 1 As a consistent risk factor for chronic pain development is the occurrence of acute pain, it is worth considering how this is managed in ICU. Those recalling higher pain and distress during ICU admission appear to be at higher risk of developing chronic pain after discharge 10 . Unfortunately, even in quiet periods on ICU, pain is an often neglected symptom receiving low priority and surprisingly poor assessment and management given the highly staffed, well-skilled environment 11 . Guidelines to improve pain assessment and management in ICU have been developed in the US and Europe, and initiatives such as the ICU Liberation ABCDEF bundles of care have been adopted in some centres. These are aimed at improving long-term outcomes through multidisciplinary management of symptoms, mobility and communication 12 , 13 . However, these processes, which often involve non-pharmacological strategies, are labour intensive and realistically may be unachievable in current pandemic conditions. Furthermore, during this outbreak, the ICU workforce has been stretched beyond its capacity with patients being treated, through necessity, by staff with rapidly scaled-up training in units with reduced staffing ratios 14 . There is therefore the potential that non-lifesaving symptomatic control may have been further neglected. The critically ill undergo a significant pain burden during everyday procedures in ICU, such as tracheal tube suctioning, turning, positioning and line insertion 15 . Due to the severity of COVID-19 critical illness it is likely that survivors will have undergone multiple pain-associated interventions. COVID-19 survivors are likely to have sustained a prolonged period of immobilisation, sedation and ventilation 5 , putting them at high risk of associated ICU-acquired weakness (ICUAW). Commonly manifesting as any combination of critical illness myopathy (CIM), critical illness polyneuropathy (CIN) and muscle atrophy, known risk factors include the use of neuromuscular blockade and corticosteroids, the presence of sepsis and multiorgan dysfunction as well as prolonged mechanical ventilation 16 . Neuromuscular blockade is now highlighted in several guideline publications as a strategy to improve ventilation in those with ARDS associated with COVID-19 17 , 18 ; although there is no consensus, some recommendations also include use of corticosteroids in certain populations 19 . The prevalence of ICUAW in the general ARDS population is estimated at 25-96%, 20 and although reported following the Middle East Respiratory Syndrome (MERS) epidemic 21 is yet to be determined in those critically ill with COVID-19. Whilst the focus of ICUAW is often the motor component, there is growing evidence for sensory disruption and associated pain. Weakness can lead to rapid deconditioning, joint related pain and contractures and, although mechanisms remain unclear, shoulder pain in particular has been highlighted as a significant problem in the post ICU population 22 . A mainstay of respiratory support through the COVID-19 pandemic has been use of repeated patient proning to improve ventilation17, 18, 19. Complications associated with proning sedated patients include brachial plexopathy, joint subluxation and soft tissue damage. These have the potential to result in persistent neuropathic and musculoskeletal pain 23 . Neuropathic symptoms including numbness, paraesthesia and pain are well documented following critical illness with abnormalities in nerve conduction studies demonstrated up to 5 years following ICU discharge 24 . Even in the absence of electrophysiological abnormalities, small nerve fibre impairment associated with neuropathic symptoms can persist for several months 25 . Reports of neurological sequelae of COVID-19 infection are emerging, indicating both central and peripheral nervous system involvement; symptoms such as confusion, headache and dizziness, as well as anosmia, ageusia and nerve pain are now described in retrospective cohorts and case reports 26 . This has led to speculation of potential neurotropism, with both muscle and neural tissue expressing Angiotensin Converting Enzyme-2 (ACE2) receptor, the functional receptor for SARS-CoV-227. The related SARS-CoV virus is also associated with neural injury, including axonopathic polyneuropathy 28 , and has been detected in both the CSF and brain tissue 29 . There are ongoing efforts to determine which human cells are susceptible to SARS-CoV-2 infection, but direct neural invasion has not yet been demonstrated 30 . Regardless of direct neural entry, SARS-CoV-2, like SARS and MERS, appears to have the capacity to induce painful para-infectious neurological disease as shown by a number of case reports of Guillan-Barre syndrome 31 and polyneuritis 32 . Thrombotic, hypotensive and hypoxaemic consequences of infection can also contribute to longstanding, potentially painful neurological sequelae such as stroke. Renal dysfunction is also common and may be associated with a peripheral neuropathy, particularly if renal impairment persists after the acute injury. A further aspect to consider is neuropathic pain as a side effect of putative therapeutic agents currently under investigation for modifying disease severity, such as lopinavir/ritonavir and hydroxychloroquine. It is now clear that COVID-19 itself is associated with painful symptoms, including myalgia, arthralgia, abdominal pain, headache and chest pain, and even those not admitted to critical care environments may have pain requiring opioids for symptom management 33 . An important area to recognise is the psychological impact of COVID-19, with the unique social restrictions likely to create an additional burden. Severe psychological sequelae have been reported in ICU survivors with up to 30% of ARDS survivors developing post-traumatic stress disorder (PTSD) 34 . In COVID-19 this may be augmented by separation from family, use of personal protective equipment (PPE) adding to the already alien environment, breakdown of social networks and fear of mortality; this increases the potential for development of PTSD, anxiety and depression, as observed in the SARS outbreak 35 . Pain is thought to have a bidirectional relationship with such psychological factors: in the acute phase it may be a risk factor contributing to the development of mental health co-morbidities, with chronic pain being a well-recognised co-morbidity. Even baseline patient characteristics, identified as factors associated with the development of severe COVID-19, overlap with those associated with chronic pain after critical illness, including multi-morbidity and increasing age 36 . It is also likely that those with pre-existing multi-morbidity were at higher risk of chronic pain prior to infection, which may predispose them to exacerbation of current or development of new pain conditions 37 . Emerging reports from Wuhan, which is now operating several rehabilitation institutions for COVID-19 survivors, and Italy indicate a significant symptom burden in COVID-19 survivors including anxiety, sleep disorders, fatigue, limited exercise tolerance as well as memory and executive function impairment 38 . Such symptoms are likely to be exacerbated or even attributed to pain although this is yet to be explored. What remains unclear is the level of rehabilitation that will be possible for different countries in the early phase of recovery. Early intervention including adequate pain management, psychological and physical therapy has the potential to reduce the risk of long-term pain as well as other features of PICS 39 . However, currently resources are focused on frontline services which may leave limited support for such an unprecedented cohort of patients. There is conflicting evidence on the beneficial effects of post-ICU rehabilitation strategies in general on exercise tolerance and health-related quality of life in the pre-COVID era. 40 , 41 Qualitative evaluation suggests increased patient satisfaction and reduced anxiety 42 . Although pain forms a component of health-related quality of life measures, specific research into the effect of post-ICU rehabilitation on pain has never been formally evaluated. The majority of studies on efficacy of pain management and post-critical illness rehabilitation have focused on face-to-face delivery, often in a group-based setting. Such traditional models of care may not be possible for some time, with ongoing social distancing and diversion of healthcare resources. We therefore must develop and assess innovative ways to deliver therapy that is accessible to those who need it. Telemedicine and promotion of self-management programmes are being explored for this cohort, and may become part of the ‘new normal’ for delivery of this type of service. Yet for some vulnerable patient groups (e.g. elderly, cognitively impaired, high deprivation) access may be problematic. Stratifying patients to high intensity or speciality specific rehabilitation through a stepped care model may be required but is difficult given the lack of specific COVID-19 research and experience. Extrapolation of best practice evidence from other cohorts will be required. Historically, rehabilitation for survivors of critical illness has been disease specific. For example, cardiac patients may get streamed to a cardiac rehabilitation pathway; those with chronic respiratory disease to pulmonary rehabilitation; those with a stroke to post-stroke resources. However this was problematic for two reasons: firstly, these classes and pathways were not designed to address the additional burden of PICS in addition to the patients underlying condition, and secondly, there was a large proportion of patients that did not fall into these categories, ‘slipped through the net’ and received suboptimal care. Several models of more contemporary general ICU follow-up clinics currently exist, 43 but they are by no means universal. It is likely that these have not been subject to the number of patients that will need their services in the foreseeable future. The make-up of such services may also need to be adjusted to address COVID-19-specific sequelae, and this may represent an opportunity to develop better links between pain and ICU survivorship programmes, as well as improving dialogue with other specialties such as renal, respiratory and mental health to build existing collaborations and manage multi-morbidity. Pain services are traditionally multidisciplinary, incorporating physical and psychological expertise with the goal of improving function and quality of life, and could therefore have a great deal to offer overwhelmed critical care services. Such integrated follow up pathways also provide an opportunity to develop embedded research and registries to learn more about the features, aetiology, risk factors and therapeutic interventions for chronic pain following critical illness, an as yet neglected area of critical care survivorship. In the rapidly changing clinical environment, flexibility and changes to health and social care delivery are required. Whilst the trajectory of this pandemic has not given us the luxury of developing a high-quality evidence base on which to base our management decisions, it is beholden on us to critically assess what we are doing. Perhaps now more than ever we need to work collaboratively to assess interventions used in rehabilitation of post-COVID-19 patients. There is the opportunity to use a similar approach to that of some clinical trials of acute interventions (such as RECOVERY (https://www.recoverytrial.net/)), where adaptive trial design allows rapid evaluation of a range of potential COVID-19 treatments. Although the acute challenges of managing COVID-19 have been significant, it may be the long-term effects, including pain, that will have the greatest impact on survivors and society, As an academic community, understanding post-COVID-19 effects and ensuring a strong evidence base for how to manage these is vital for patients, health and social care systems, and for policy makers. Authors’ contributions LC and HK devised the topic of the manuscript; HK, LC, EC drafted sections for and finalised the manuscript. Declaration of interests LC is an editor for the British Journal of Anaesthesia. HK is a fellow with the British Journal of Anaesthesia Peer Review Fellowship Programme. Funding National Institute for Health Research (HK). Uncited References 27.

          Related collections

          Most cited references32

          • Record: found
          • Abstract: found
          • Article: not found

          Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

          Summary Background An ongoing outbreak of pneumonia associated with the severe acute respiratory coronavirus 2 (SARS-CoV-2) started in December, 2019, in Wuhan, China. Information about critically ill patients with SARS-CoV-2 infection is scarce. We aimed to describe the clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia. Methods In this single-centered, retrospective, observational study, we enrolled 52 critically ill adult patients with SARS-CoV-2 pneumonia who were admitted to the intensive care unit (ICU) of Wuhan Jin Yin-tan hospital (Wuhan, China) between late December, 2019, and Jan 26, 2020. Demographic data, symptoms, laboratory values, comorbidities, treatments, and clinical outcomes were all collected. Data were compared between survivors and non-survivors. The primary outcome was 28-day mortality, as of Feb 9, 2020. Secondary outcomes included incidence of SARS-CoV-2-related acute respiratory distress syndrome (ARDS) and the proportion of patients requiring mechanical ventilation. Findings Of 710 patients with SARS-CoV-2 pneumonia, 52 critically ill adult patients were included. The mean age of the 52 patients was 59·7 (SD 13·3) years, 35 (67%) were men, 21 (40%) had chronic illness, 51 (98%) had fever. 32 (61·5%) patients had died at 28 days, and the median duration from admission to the intensive care unit (ICU) to death was 7 (IQR 3–11) days for non-survivors. Compared with survivors, non-survivors were older (64·6 years [11·2] vs 51·9 years [12·9]), more likely to develop ARDS (26 [81%] patients vs 9 [45%] patients), and more likely to receive mechanical ventilation (30 [94%] patients vs 7 [35%] patients), either invasively or non-invasively. Most patients had organ function damage, including 35 (67%) with ARDS, 15 (29%) with acute kidney injury, 12 (23%) with cardiac injury, 15 (29%) with liver dysfunction, and one (2%) with pneumothorax. 37 (71%) patients required mechanical ventilation. Hospital-acquired infection occurred in seven (13·5%) patients. Interpretation The mortality of critically ill patients with SARS-CoV-2 pneumonia is considerable. The survival time of the non-survivors is likely to be within 1–2 weeks after ICU admission. Older patients (>65 years) with comorbidities and ARDS are at increased risk of death. The severity of SARS-CoV-2 pneumonia poses great strain on critical care resources in hospitals, especially if they are not adequately staffed or resourced. Funding None.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China

            The outbreak of coronavirus disease 2019 (COVID-19) in Wuhan, China, is serious and has the potential to become an epidemic worldwide. Several studies have described typical clinical manifestations including fever, cough, diarrhea, and fatigue. However, to our knowledge, it has not been reported that patients with COVID-19 had any neurologic manifestations.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Covid-19 in Critically Ill Patients in the Seattle Region — Case Series

              Abstract Background Community transmission of coronavirus 2019 (Covid-19) was detected in the state of Washington in February 2020. Methods We identified patients from nine Seattle-area hospitals who were admitted to the intensive care unit (ICU) with confirmed infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Clinical data were obtained through review of medical records. The data reported here are those available through March 23, 2020. Each patient had at least 14 days of follow-up. Results We identified 24 patients with confirmed Covid-19. The mean (±SD) age of the patients was 64±18 years, 63% were men, and symptoms began 7±4 days before admission. The most common symptoms were cough and shortness of breath; 50% of patients had fever on admission, and 58% had diabetes mellitus. All the patients were admitted for hypoxemic respiratory failure; 75% (18 patients) needed mechanical ventilation. Most of the patients (17) also had hypotension and needed vasopressors. No patient tested positive for influenza A, influenza B, or other respiratory viruses. Half the patients (12) died between ICU day 1 and day 18, including 4 patients who had a do-not-resuscitate order on admission. Of the 12 surviving patients, 5 were discharged home, 4 were discharged from the ICU but remained in the hospital, and 3 continued to receive mechanical ventilation in the ICU. Conclusions During the first 3 weeks of the Covid-19 outbreak in the Seattle area, the most common reasons for admission to the ICU were hypoxemic respiratory failure leading to mechanical ventilation, hypotension requiring vasopressor treatment, or both. Mortality among these critically ill patients was high. (Funded by the National Institutes of Health.)
                Bookmark

                Author and article information

                Contributors
                Journal
                Br J Anaesth
                Br J Anaesth
                BJA: British Journal of Anaesthesia
                Published by Elsevier Ltd on behalf of British Journal of Anaesthesia.
                0007-0912
                1471-6771
                31 May 2020
                31 May 2020
                Affiliations
                [1 ]Pain Research Group, Imperial College London, London, UK
                [2 ]Department of Clinical Sciences, Brunel University London, London, UK
                [3 ]Division of Population Health & Genomics, University of Dundee, Ninewells Hospital and Medical School, Dundee, UK
                Author notes
                []Corresponding author. h.kemp@ 123456imperial.ac.uk
                Article
                S0007-0912(20)30403-7
                10.1016/j.bja.2020.05.021
                7261464
                32560913
                bd109d5d-e9f9-446d-9c8f-b74c38ad8835
                © 2020 Published by Elsevier Ltd on behalf of British Journal of Anaesthesia.

                Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

                History
                : 14 May 2020
                : 21 May 2020
                : 22 May 2020
                Categories
                Article

                Anesthesiology & Pain management
                chronic pain,covid-19,critical care,icu-acquired weakness,post-intensive care syndrome,recovery,rehabilitation,sars-cov-2,survivor

                Comments

                Comment on this article